Before the US stock market on Monday, BioNTech released its second-quarter earnings report. With the spread of COVID-19, COVID-19 vaccine sales soared, and this also caused BioNTech, which cooperated with Pfizer to produce vaccines, to skyrocket 130 times year-on-year in revenue, much higher than market expectations.
Key figures in BioNTech's second quarter earnings report are as follows:
Revenue for the quarter: 5.31 billion euros, far higher than the 41.7 million euros in the same period last year, and also higher than the market's previous forecast of 3.5 billion euros. Operating profit for the quarter: 4.2 billion euros, higher than market expectations of 2.95 billion euros. Net profit for the quarter: 2.79 billion euros, which turned a loss into a profit compared to last year. At that time, it was a loss of 88 million euros.
In addition, BioNTech also pointed out in its financial report that it has raised the sales forecast for the COVID-19 vaccine to 15.9 billion euros this year. The above forecast is based on the contract for the supply of about 2.2 billion doses of the vaccine that has been signed so far. Also, the reason why BioNTech's second-quarter revenue and profit data soared is mainly because the company has sold hundreds of millions of doses of the COVID-19 vaccine with its US partner Pfizer.
BioNTech CEO and co-founder Ugur Sahin said in a financial press release published on the official website that the global shipment volume of the COVID-19 vaccine produced by the company in collaboration with Pfizer broke through the 1 billion dose mark in just six months, and the company is also expanding the supply of the vaccine to more than 100 countries around the world...